S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
How to use A.I. to trade during an election year? (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
How to profit from the new boom in gold (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
How to profit from the new boom in gold (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
How to use A.I. to trade during an election year? (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
How to profit from the new boom in gold (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
How to profit from the new boom in gold (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
How to use A.I. to trade during an election year? (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
How to profit from the new boom in gold (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
How to profit from the new boom in gold (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
How to use A.I. to trade during an election year? (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
How to profit from the new boom in gold (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
How to profit from the new boom in gold (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands

Nuformix (NFX) Competitors

GBX 0.20
-0.06 (-24.23%)
(As of 05:02 AM ET)

NFX vs. PYC, RENE, FAB, EVG, OVB, APTA, IXI, IMM, GENF, and OCTP

Should you be buying Nuformix stock or one of its competitors? The main competitors of Nuformix include Physiomics (PYC), ReNeuron Group (RENE), Fusion Antibodies (FAB), Evgen Pharma (EVG), Ovoca Bio (OVB), Aptamer Group (APTA), IXICO (IXI), ImmuPharma (IMM), Genflow Biosciences (GENF), and Oxford Cannabinoid Technologies (OCTP). These companies are all part of the "biotechnology" industry.

Nuformix vs.

Nuformix (LON:NFX) and Physiomics (LON:PYC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Nuformix has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Physiomics has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500.

Nuformix has a net margin of 0.00% compared to Physiomics' net margin of -78.79%. Nuformix's return on equity of -27.25% beat Physiomics' return on equity.

Company Net Margins Return on Equity Return on Assets
NuformixN/A -27.25% -17.20%
Physiomics -78.79%-63.36%-40.04%

Physiomics received 12 more outperform votes than Nuformix when rated by MarketBeat users. However, 66.67% of users gave Nuformix an outperform vote while only 55.56% of users gave Physiomics an outperform vote.

CompanyUnderperformOutperform
NuformixOutperform Votes
68
66.67%
Underperform Votes
34
33.33%
PhysiomicsOutperform Votes
80
55.56%
Underperform Votes
64
44.44%

Physiomics has higher revenue and earnings than Nuformix.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuformix£50K38.70-£1.20MN/AN/A
Physiomics£900.71K1.96N/AN/AN/A

In the previous week, Nuformix's average media sentiment score of 0.00 equaled Physiomics'average media sentiment score.

Company Overall Sentiment
Nuformix Neutral
Physiomics Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuformix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Physiomics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

0.2% of Nuformix shares are owned by institutional investors. Comparatively, 0.1% of Physiomics shares are owned by institutional investors. 16.5% of Nuformix shares are owned by insiders. Comparatively, 6.3% of Physiomics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Nuformix beats Physiomics on 8 of the 11 factors compared between the two stocks.


Get Nuformix News Delivered to You Automatically

Sign up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NFX vs. The Competition

MetricNuformixBiotechnology IndustryMedical SectorLON Exchange
Market Cap£1.94M£224.57M£4.90B£1.33B
Dividend YieldN/A3.53%2.88%12.14%
P/E Ratio-1.63110.68219.841,650.30
Price / Sales38.7025,572.873,282.37429,609.30
Price / Cash3.5511.5295.1432.90
Price / Book0.265.864.472.50
Net Income-£1.20M-£15.46M£114.07M£183.33M
7 Day Performance-6.81%-0.11%4.84%-0.26%
1 Month Performance-18.75%3.43%10.08%-0.47%
1 Year Performance-26.76%73.55%12.30%6.01%

Nuformix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PYC
Physiomics
0 of 5 stars
GBX 1.45
-3.3%
N/A-68.7%£1.96M£900,707.00-13.8310Gap Up
RENE
ReNeuron Group
0 of 5 stars
GBX 3.38
-2.2%
N/A-67.5%£1.93M£783,000.00-37.5026Gap Down
FAB
Fusion Antibodies
0 of 5 stars
GBX 3.89
-0.2%
N/A-92.4%£2.32M£1.58M-43.2748
EVG
Evgen Pharma
0 of 5 stars
GBX 1.07
-2.8%
N/A-75.0%£2.94MN/A-106.9010News Coverage
OVB
Ovoca Bio
0 of 5 stars
GBX 0.85
flat
N/A-84.9%£693,000.00N/A-42.505
APTA
Aptamer Group
0 of 5 stars
GBX 0.79
-10.8%
N/A-98.2%£3.67M£1.75M-7.1446Gap Down
IXI
IXICO
0 of 5 stars
GBX 8.75
flat
N/A-65.3%£4.23M£6.67M-437.5089
IMM
ImmuPharma
0 of 5 stars
GBX 1.08
-2.4%
N/A-54.0%£4.49M£94,819.00-107.9013Gap Down
GENF
Genflow Biosciences
0 of 5 stars
GBX 1.55
flat
N/A-34.4%£4.53MN/A-256.005Gap Up
OCTP
Oxford Cannabinoid Technologies
0 of 5 stars
GBX 0.46
+3.4%
N/A-42.2%£4.96MN/A-53.107Gap Up

Related Companies and Tools

This page (LON:NFX) was last updated on 3/1/2024 by MarketBeat.com Staff